Understanding Extramammary Paget's Disease in Women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on women diagnosed with Extramammary Paget's Disease (EMPD) of the vulva and perianal region. It aims to evaluate treatment outcomes while collecting tissue samples and swabs to analyze the microbiome associated with the affected skin areas. Participants will complete various sexual health questionnaires and undergo preoperative genital sensory testing. The study is conducted at the Mayo Clinic, where patients will receive care and may undergo surgical interventions as needed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Females
* Age 18 years or older
* Diagnosed with primary or recurrent EMPD of vulva and/or perianal region of the body
* Willing and able to provide signed informed consent

Exclusion Criteria:

* Males
* Diagnosis of Paget's Disease in body areas other than vulvar or perianal region

Where it's running

• Mayo Clinic
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Jamie N. Bakkum-Gamez, M.D. — Mayo Clinic
• Study coordinator: Maureen A. Lemens, R.N.
• Email: lemens.maureen@mayo.edu
• Phone: 507-293-1487

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Disitamab Vedotin plus bicalutamide for HER2/AR-positive scrotal Paget disease

  This trial will test whether combining Disitamab Vedotin and bicalutamide helps adults with advanced HER2-positive, AR-positive extramammary Paget disease of the scrotum.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07117851

• Using fluorescein sodium to assist in vulvectomy for extramammary Paget's disease

  This study is testing if giving a special dye before surgery can help doctors find and remove cancerous cells more effectively in patients with extramammary Paget's disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06873815

• Treatment for advanced extramammary Paget disease of the scrotum

  This study is testing a new combination of two drugs to see if they can help people with advanced HER2-positive extramammary Paget disease of the scrotum feel better and reduce their tumor size.

  Recruiting Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06791070

• Treatment of rare advanced tumors with a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with rare advanced tumors live longer and feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06684327

• Using Ivocizumab to treat various advanced rare tumors

  This study is testing if a new treatment called Ivocizumab can help people with different types of advanced rare tumors feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06683846

• MQ710 with or without pembrolizumab for advanced skin and other solid tumors

  This will test different doses of MQ710, alone or together with pembrolizumab, in adults with advanced or recurrent solid tumors (including skin cancers) to find a safe dose with mild side effects.

  Recruiting at 5 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05859074

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.